期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 15, 期 10, 页码 2482-2490出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2019.1591139
关键词
Anti-integrin therapy; Crohn's disease; gut-selective; inflammatory bowel disease; ulcerative colitis; vedolizumab
资金
- American Gastroenterological Association [AGA]
Vedolizumab is a monoclonal antibody to the alpha 4 beta 7 integrin that selectively reduces intestinal lymphocyte trafficking, thereby providing a safe and effective treatment option for patients with inflammatory bowel disease (IBD). This product review outlines the unique mechanism of vedolizumab in addition to efficacy, safety, pharmacokinetic and pharmacodynamic data from clinical trials, observational studies and meta-analyses. Vedolizumab has been shown to be effective as a first- or second-line induction and maintenance therapy in both ulcerative colitis (UC) and Crohn's disease (CD). Prolonged induction therapy may increase efficacy, particularly in tumor necrosis factor-alpha-exposed CD patients. To date, no drug-specific safety signals have been identified. In addition to the presence of an apparent exposure-response relationship, vedolizumab has demonstrated consistent pharmacodynamic effects on alpha 4 beta 7, mucosal vascular addressin cell adhesion molecule 1 and other cell adhesion molecules. Future efforts should focus on identifying predictive biomarkers capable of guiding personalized IBD treatment with vedolizumab.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据